Abiopharma

SILEXION THERAPEUTICS CORP (SLXNW)

Symbol	SLXNW
Name	SILEXION THERAPEUTICS CORP
Sector	HEALTH CARE
Region	Middle East
Industry	Biotechnology: Biological Products (No Diagnostic Substances)
Address	12 ABBA HILLEL ROAD, RAMAT-GAN, Illinois, 5250606, United States
Telephone	+972 3 - 756-4999
Fax	—
Email	—
Website	https://silexion.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0002022416
Description	Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel. Additional info from NASDAQ: Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

2026-08-26 02:29

SLXNW attributes changed: Attr: Fin_status N -> D;

2026-08-26 02:29

SLXN attributes changed: Attr: Fin_status N -> D;

2026-08-25 09:37

New Form DEF 14A - Silexion Therapeutics Corp Filed: 2026-08-24 AccNo: 0001178913-26-004243 Size: 251 KB

2026-08-19 21:19

New Form SCHEDULE 13D/A - Silexion Therapeutics Corp Filed: 2026-08-19 AccNo: 0001213900-26-091845 Size: 30 KB

2026-08-18 18:37

New Form SCHEDULE 13G - Silexion Therapeutics Corp Filed: 2026-08-18 AccNo: 0001213900-26-091333 Size: 18 KB

2026-08-14 17:32

New Form PRE 14A - Silexion Therapeutics Corp Filed: 2026-08-14 AccNo: 0001178913-26-004145 Size: 254 KB

2026-08-14 12:45

Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

2026-08-13 21:06

(75% Positive) SILEXION THERAPEUTICS CORP (SLXN) Files Form 8-K

2026-08-13 20:02

(70% Positive) SILEXION THERAPEUTICS CORP (SLXN) Provides Update on agent for general corporate purposes

2026-08-13 12:01

New Form 424B4 - Silexion Therapeutics Corp Filed: 2026-08-13 AccNo: 0001178913-26-004116 Size: 3 MB

No clinical trials found for this company.

No clinical products found for this company.